After touching lows of $0.90, $RNXT has seen a solid recovery, surging by over 20% within the last 10 days. The price has broken through key resistance levels and is currently trading above the 50-day moving average, signaling potential for continued momentum. Increased volume and positive MACD crossovers indicate that bullish sentiment may be building.

1. Price Movement: The stock is moving within a defined range, with a recent uptrend. The price recently broke through a resistance level, which may suggest a bullish sentiment.
2. Moving Averages: The chart includes a 50-day moving average line (in blue), currently at around 0.9967, which is being used as a support level.
3. MACD Indicator: The MACD shows a slight positive momentum, indicating potential for upward movement if the trend continues.
4. Volume: Volume bars indicate some recent spikes, suggesting increased trading activity which can lead to more volatility.

Next target: Watching to see if it can hold above $1.05 and aim for higher resistance levels.  Keep an eye on volume and moving averages for confirmation of this uptrend.

RenovoRx's recent increase in production of the FDA-cleared RenovoCath catheter-based delivery system marks a significant catalyst for the company's growth. This expansion is in response to rising demand from oncologists and interventional radiologists, signaling growing acceptance of RenovoCath for targeted drug delivery. By enhancing its manufacturing capacity through a partnership with Medical Murray and issuing performance-based equity incentives, RenovoRx is effectively positioning itself to meet the increasing demand and explore new commercial opportunities. These initiatives could accelerate the company’s path to revenue generation, further supported by ongoing efforts to commercialize RenovoCath as a standalone device, beyond the current clinical programs.

• Increased Manufacturing Capacity: Partnership with Medical Murray expands production of RenovoCath, addressing higher demand.
• Standalone Device Sales: Exploring commercial opportunities for RenovoCath beyond ongoing trials, indicating multiple potential revenue streams.
• Revenue Generation Path: Targeting revenue growth in 2025 with ongoing discussions for supply and distribution partnerships.
• Key Personnel Promotion: Robert Strasser promoted to Vice President of R&D and Operations, supporting commercialization efforts.
• Financial Readiness: Sufficient cash reserves to fund upcoming clinical milestones and commercial activities.
• Communicated Disclaimer: Let me know what you think. Is there hope or is this the end of the line? Here are some sources - 1, 2, 3, 4